These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21437168)

  • 1. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia.
    Sohn KM; Kang CI; Joo EJ; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
    Korean J Intern Med; 2011 Mar; 26(1):89-93. PubMed ID: 21437168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
    Ahn JY; Ann HW; Jeon Y; Ahn MY; Oh DH; Kim YC; Kim EJ; Song JE; Jung IY; Kim MH; Jeong W; Ku NS; Jeong SJ; Choi JY; Yong D; Song YG; Kim JM
    BMC Infect Dis; 2017 May; 17(1):327. PubMed ID: 28468622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis.
    Kurihara Y; Hitomi S; Oishi T; Kondo T; Ebihara T; Funayama Y; Kawakami Y
    J Infect Chemother; 2013 Oct; 19(5):799-805. PubMed ID: 23371453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
    Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
    Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
    Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.
    Paterson DL; Mulazimoglu L; Casellas JM; Ko WC; Goossens H; Von Gottberg A; Mohapatra S; Trenholme GM; Klugman KP; McCormack JG; Yu VL
    Clin Infect Dis; 2000 Mar; 30(3):473-8. PubMed ID: 10722430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
    Kanayama A; Kobayashi I; Shibuya K
    Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia.
    Lee CC; Lee CH; Hong MY; Hsieh CC; Tang HJ; Ko WC
    J Microbiol Immunol Infect; 2018 Aug; 51(4):519-526. PubMed ID: 28698042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial Susceptibility and Molecular Epidemiology of
    Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
    Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum β-lactamase-producing Proteus mirabilis with multidrug resistance isolated from raw chicken in Singapore: Genotypic and phenotypic analysis.
    Guo S; Aung KT; Tay MYF; Seow KLG; Ng LC; Schlundt J
    J Glob Antimicrob Resist; 2019 Dec; 19():252-254. PubMed ID: 31639544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
    Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
    J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
    Kwiecińska-Piróg J; Bogiel T; Gospodarek E
    Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002.
    Ho PL; Ho AY; Chow KH; Wong RC; Duan RS; Ho WL; Mak GC; Tsang KW; Yam WC; Yuen KY
    J Antimicrob Chemother; 2005 Jun; 55(6):840-5. PubMed ID: 15857942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia.
    Tonkić M; Mohar B; Šiško-Kraljević K; Meško-Meglič K; Goić-Barišić I; Novak A; Kovačić A; Punda-Polić V
    J Med Microbiol; 2010 Oct; 59(Pt 10):1185-1190. PubMed ID: 20558587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical epidemiology of ciprofloxacin resistance and its relationship to broad-spectrum cephalosporin resistance in bloodstream infections caused by Enterobacter species.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Infect Control Hosp Epidemiol; 2005 Jan; 26(1):88-92. PubMed ID: 15693414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.